dasotraline Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Dasotraline is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that was under development by Sunovion for the treatment of attention-deficit hyperactivity disorder (ADHD) and binge eating disorder (BED). Structurally, dasotraline is a stereoisomer of desmethylsertraline (DMS), which is an active metabolite of the marketed selective serotonin reuptake inhibitor (SSRI) antidepressant sertraline (Zoloft).   Wikipedia

Chemistry

  • SMILES: N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c3ccccc13
  • InChIKey: SRPXSILJHWNFMK-MEDUHNTESA-N
  • Mol. Mass: 292.21
  • ALogP: 4.92
  • ChEMBL Molecule:
    dasotraline  
More Chemistry

Pharmacology

Alternative names

4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine | dasotraline | sep225289 | sep 225289 | sep-225289

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Attention Deficit and Disruptive Behavior Disorders (Phase 3)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Binge-Eating Disorder (Phase 3)

Depressive Disorder, Major (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue